Abstract |
The purpose of our study is to identify the efficacy of ruxolitinib in human leukocyte antigen (HLA) haploidentical hematopoietic stem cell transplantation (haplo-HSCT) recipients with multidrug-resistant (MDR)- graft-versus-host disease (GVHD, n = 34). MDR-GVHD was defined as GVHD showing no improvement after at least 3 types of treatments. The median number of previous GVHD- therapies was 4 for both MDR-acute GVHD (aGVHD) and MDR-chronic GVHD (cGVHD). For MDR-aGVHD (n = 15), the median time to response was 10 days (range 2 to 65), and the overall response rate (ORR) was 60.0% (9/15), including 40.0% (6/15) complete response (CR) and 20.0% (3/15) partial response (PR). The 1-year probability of overall survival after ruxolitinib was 66.7%. The rates of hematologic and infectious toxicities were 73.3% and 46.7% after ruxolitinib treatment. For MDR-cGVHD (n = 19), the median time to response was 29 days (range 6 to 175), and the ORR was 89.5% (17/19), including 26.3% (5/19) CR and 63.2% (12/19) PR. All patients remained alive until our last follow-up. The rates of hematologic and infectious toxicities were 36.8% and 47.4% after ruxolitinib treatment. Ruxolitinib is an effective salvage treatment for MDR-GVHD in haplo-HSCT recipients.
|
Authors | Jiao-Yu Zhao, Si-Ning Liu, Lan-Ping Xu, Xiao-Hui Zhang, Yu Wang, Yu-Hong Chen, Kai-Yan Liu, Xiao-Jun Huang, Xiao-Dong Mo |
Journal | Annals of hematology
(Ann Hematol)
Vol. 100
Issue 1
Pg. 169-180
(Jan 2021)
ISSN: 1432-0584 [Electronic] Germany |
PMID | 33159239
(Publication Type: Journal Article)
|
Chemical References |
- Nitriles
- Pyrazoles
- Pyrimidines
- ruxolitinib
- Cyclophosphamide
|
Topics |
- Adolescent
- Adult
- Child
- Child, Preschool
- Cyclophosphamide
- Drug Resistance, Multiple
(drug effects, physiology)
- Female
- Follow-Up Studies
- Graft vs Host Disease
(diagnosis, drug therapy)
- Hematopoietic Stem Cell Transplantation
(trends)
- Humans
- Male
- Middle Aged
- Nitriles
- Pyrazoles
(therapeutic use)
- Pyrimidines
- Retrospective Studies
- Salvage Therapy
(trends)
- Transplantation, Haploidentical
(trends)
- Transplantation, Homologous
(trends)
- Treatment Outcome
- Young Adult
|